In today’s dynamic pharmaceutical landscape, post-approval research and post-market surveillance are essential components of ensuring that medications remain safe, effective, and relevant to real-world use. Despite their importance, these elements are often underemphasized in regulatory modeling and underresourced in practice. A recent critique of the U.S. Congressional Budget Office’s (CBO) drug development model highlighted this issue, calling for broader inclusion of post-market activities in policy evaluation frameworks (Axelsen & Miller, 2025).

For professionals trained by or aligned with the GMDP Academy, understanding and addressing these gaps isn’t just relevant—it’s a professional imperative.

The Importance of Post-Approval Research

Post-approval studies can reveal new indications, refine dosage strategies, and expand access through new formulations. Axelsen and Miller (2025) underscore this with examples like lisinopril, which gained multiple critical indications well after its initial approval. Yet, policy changes such as drug pricing reforms or shortened exclusivity windows can deter firms from investing in these vital studies.

This aligns with broader concerns documented in Frontiers in Pharmacology, which argue for an integrated, systems-based approach to medicines development that includes post-market feedback and health outcomes as essential feedback loops (Silva et al., 2021).

Challenges in Post-Market Surveillance

Several structural and operational challenges persist in post-market surveillance (PMS):

  • Underreporting of Adverse Events: Despite systems like FAERS, only a small percentage of adverse reactions are reported, which limits risk signal detection (Pharmacovigilance, 2024).
  • Regulatory Enforcement Limitations: While the FDA has authority to mandate postmarketing requirements (PMRs) under the FDA Amendments Act of 2007, enforcement remains limited in practice. The agency rarely imposes penalties, even though it technically has the power to levy fines for noncompliance (Oncology News Central, 2024).
  • Data and Operational Complexity: Inconsistent global regulatory standards, poor data integration, and challenges in collecting real-world evidence delay timely interventions (Lindus Health, 2024).

Recent reforms like the 2022 Food and Drug Omnibus Reform Act (FDORA) aim to improve oversight by enabling the FDA to withdraw accelerated approvals more quickly if required post-approval studies are not conducted (Cooley, 2023). However, meaningful enforcement and industry compliance remain inconsistent.

The Educational Response: Competency-Based Training

For GMDP Academy, these gaps represent a powerful rationale for continued investment in education. Modules such as “Regulatory Affairs, Drug Safety and Pharmacovigilance” and “Medical Affairs as a Strategic Business Partner” directly address the lifecycle approach needed in modern pharmaceutical development.

The Academy’s Certification in Medicines Development (CMD) program, offered in partnership with King’s College London, emphasizes not only regulatory science but also ethical leadership, data literacy, and health systems thinking. In a 7-year outcome evaluation, 70% of alumni reported improved performance in their professional roles, particularly in areas related to post-approval strategy and communication (Silva et al., 2024).

Conclusion: Training for the Full Lifecycle

As global regulatory and policy frameworks evolve, the need for post-approval vigilance and innovation has never been clearer. The gaps in enforcement and the complexity of real-world data demand not just better tools, but better-trained professionals.

GMDP Academy is committed to filling this void by preparing professionals to lead in post-market research, navigate regulatory landscapes, and drive patient-centric outcomes. By investing in competency-based education that spans the full lifecycle of medicines, we are building a future-ready workforce—one equipped not just to comply with regulations, but to shape them.

References

Axelsen, K., & Miller, B. J. (2025, May 19). Modeling drug development: Improvements still needed. AEIdeas. https://www.aei.org/health-care/modeling-drug-development-improvements-still-needed/

Cooley LLP. (2023, January 31). FDORA changes to the FDA Accelerated Approval Program. https://www.cooley.com/news/insight/2023/2023-01-31-fdora-changes-to-the-fda-accelerated-approval-program

Lindus Health. (2024). Understanding clinical phase 4 post-market surveillance and its importance. https://www.lindushealth.com/blog/understanding-clinical-phase-4-post-market-surveillance-and-its-importance

Oncology News Central. (2024). FDA urged to levy fines for delayed confirmatory trials in oncology and beyond. https://www.oncologynewscentral.com/article/fda-urged-to-levy-fines-for-delayed-confirmatory-trials-in-oncology-and-beyond

Pharmacovigilance. (2024). In Wikipedia. https://en.wikipedia.org/wiki/Pharmacovigilance

Silva, H., Stonier, P. D., Kerpel-Fronius, S., & Dubois, D. J. (2021). Editorial: Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. Frontiers in Pharmacology, 12, 666406. https://doi.org/10.3389/fphar.2021.666406:contentReference[oaicite:2]{index=2}

Silva, H., Stonier, P., Chopra, P., et al. (2024). Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King’s College, London and the GMDP Academy, New York. Frontiers in Pharmacology, 15, 1417036. https://doi.org/10.3389/fphar.2024.1417036:contentReference[oaicite:3]{index=3}

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred